EIGRQ — Eiger Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
- 37
- 38
- 94
- 56
Annual income statement for Eiger Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 12.1 | 13.5 | 15.8 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 11.4 | 11.6 | 15.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 68.9 | 62.1 | 89.1 | 107 | 87.6 |
| Operating Profit | -68.9 | -62.1 | -76.9 | -93.8 | -71.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -70.3 | -65.1 | -33.9 | -96.8 | -75 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -70.3 | -65.1 | -33.9 | -96.8 | -75 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -70.3 | -65.1 | -33.9 | -96.8 | -75 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -70.3 | -65.1 | -33.9 | -96.8 | -75 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -92.5 | -69.3 | -30 | -69.2 | -50.8 |